[{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Amgen Inc"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azathioprine","moa":"||IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azathioprine","moa":"DNA | Amidophosphoribosyltransferase","graph1":"Immunology","graph2":"Phase IV","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinese SLE Treatment And Research Group \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Chinese SLE Treatment And Research Group \/ Inapplicable"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Azathioprine","moa":"DNA | Amidophosphoribosyltransferase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nantes University Hospital \/ Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","highestDevelopmentStatusID":"1","companyTruncated":"Nantes University Hospital \/ Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives"}]

Find Clinical Drug Pipeline Developments & Deals for Azathioprine Sodium USP

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Chinese SLE Treatment And Research Group

                          Country arrow
                          EPSC
                          Not Confirmed

                          Chinese SLE Treatment And Research Group

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 28, 2023

                          Lead Product(s) : Azathioprine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Nantes University Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          Nantes University Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Azathioprine

                          Therapeutic Area : Immunology

                          Study Phase : Undisclosed

                          Sponsor : Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 18, 2022

                          Lead Product(s) : Azathioprine

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Leading those recommendations is Roche’s Enspryng (satralizumab), which received a positive opinion for the treatment of the rare autoimmune disease neuromyelitis optica spectrum disorders (NMOSD).

                          Product Name : Enspryng

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 23, 2021

                          Lead Product(s) : Satralizumab,Azathioprine,Mycophenolate Mofetil

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The NDA included data from the global, Phase III ADVOCATE trial, which demonstrated statistical superiority in sustaining remission at 52 weeks in the avacopan group compared to the prednisone group.

                          Product Name : Tavneos

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 17, 2020

                          Lead Product(s) : Avacopan,Azathioprine,Rituximab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The study showed that avacopan was as effective as prednisone therapy in bringing patients into remission by 26 weeks, and superior to prednisone for sustained remission after 52 weeks.

                          Product Name : Tavneos

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 11, 2020

                          Lead Product(s) : Avacopan,Azathioprine,Rituximab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : If approved, avacopan would be the first orally administered selective complement 5a receptor inhibitor, for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.

                          Product Name : Tavneos

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 11, 2020

                          Lead Product(s) : Avacopan,Azathioprine,Rituximab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Amgen Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Azathioprine

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Medicines Evaluation Unit | Syne Qua Non Limited | Alderley Analytical | Black County Pathology Services | Diamond Pharma Services | Boyd Consultants

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 29, 2019

                          Lead Product(s) : Azathioprine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Medicines Evaluation Unit | Syne Qua Non Limited | Alderley Analytical | Black County Pathology Services | Diamond Pharma Services | Boyd Consultants

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Kyungpook National University Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          Kyungpook National University Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 20, 2015

                          Lead Product(s) : Azathioprine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase IV

                          Sponsor : Celltrion

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

                          Country arrow
                          EPSC
                          Not Confirmed

                          Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 24, 2015

                          Lead Product(s) : Azathioprine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 13, 2013

                          Lead Product(s) : Azathioprine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank